IS-free Treg HaploHCT

Summary

IS-free Treg HaploHCT is a clinical trial^[1].

Key Facts

• IS-free Treg HaploHCT is in the country of United States^[2].
• IS-free Treg HaploHCT's instance of is recorded as clinical trial^[3].
• IS-free Treg HaploHCT's start time is recorded as +2021-01-31T00:00:00Z^[4].
• IS-free Treg HaploHCT's end time is recorded as +2021-10-31T00:00:00Z^[5].
• IS-free Treg HaploHCT's main subject is recorded as acute myeloid leukemia^[6].
• IS-free Treg HaploHCT's main subject is recorded as leukemia^[7].
• IS-free Treg HaploHCT's number of participants is recorded as {'unit': '1', 'amount': '+10'}^[8].
• IS-free Treg HaploHCT's title is recorded as A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory AML/MDS^[9].
• IS-free Treg HaploHCT's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• IS-free Treg HaploHCT's ClinicalTrials.gov ID is recorded as NCT04678401^[11].
• IS-free Treg HaploHCT's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[12].
• IS-free Treg HaploHCT's research intervention is recorded as (RS)-cyclophosphamide^[13].
• IS-free Treg HaploHCT's research intervention is recorded as thiotepa^[14].
• IS-free Treg HaploHCT's research intervention is recorded as fludarabine phosphate^[15].
• IS-free Treg HaploHCT's clinical trial phase is recorded as phase I clinical trial^[16].
• IS-free Treg HaploHCT's research site is recorded as Dana–Farber Cancer Institute^[17].
• IS-free Treg HaploHCT's research subject recruitment status is recorded as not yet recruiting^[18].
• IS-free Treg HaploHCT's study type is recorded as interventional study^[19].